Detalles de la búsqueda
1.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Oncologist
; 29(4): 303-310, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995313
2.
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.
J Transl Med
; 22(1): 329, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38570798
3.
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
BMC Cancer
; 24(1): 430, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589857
4.
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Support Care Cancer
; 32(3): 202, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427111
5.
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.
Int J Mol Sci
; 25(7)2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38612563
6.
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Cancer Immunol Immunother
; 72(11): 3707-3716, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37638980
7.
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
Curr Oncol Rep
; 25(11): 1345-1362, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37855848
8.
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer.
Int J Mol Sci
; 24(15)2023 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37569810
9.
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Int J Mol Sci
; 24(2)2023 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36674615
10.
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Breast Cancer Res
; 24(1): 71, 2022 10 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36307826
11.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462870
12.
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
J Transl Med
; 20(1): 435, 2022 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36180954
13.
Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma: a case report.
Anticancer Drugs
; 33(1): 105-108, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232938
14.
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
Int J Mol Sci
; 23(5)2022 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35269621
15.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer
; 125(6): 839-845, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253871
16.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33024268
17.
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
J Transl Med
; 19(1): 328, 2021 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34344414
18.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34167578
19.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci
; 18(10): 2245-2250, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33859534
20.
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens.
Chemotherapy
; 66(5-6): 161-168, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34644703